Business, energy, technology, markets and global industry news from Business News Today

enfortumab vedotin

PharmaDeviceNews enfortumab vedotin
Innate Pharma’s IPH4502 Phase 1 dose-escalation milestone advances its Nectin-4 exatecan ADC toward a 76-patient year-end readout in advanced solid tumors. Representative image.
Pharma & Biotech

Why Innate Pharma’s 76-patient IPH4502 milestone is only half the Nectin-4 story

Innate Pharma completed IPH4502 dose-escalation enrollment, putting safety, response durability and dose selection at the center of a year-end readout.

Read More
FDA approval of Keytruda and Keytruda Qlex with Padcev expands perioperative treatment options for adults with muscle-invasive bladder cancer. Representative image.
Pharma & Biotech

Can Keytruda plus Padcev replace cisplatin chemotherapy before bladder cancer surgery?

FDA approval moves Keytruda and Padcev into perioperative MIBC regardless of cisplatin eligibility, intensifying the contest for standard care.

Read More
FDA approval of Padcev plus Keytruda expands perioperative treatment options for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. Representative image.
Pharma & Biotech

Pfizer and Astellas secure wider FDA label for Padcev plus Keytruda in muscle-invasive bladder cancer

FDA expands Padcev plus Keytruda to adults with muscle-invasive bladder cancer regardless of cisplatin eligibility, reshaping perioperative care.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
A representative image of bladder cancer treatment. As PADCEV and Keytruda show promise in transforming perioperative care, new platinum-free regimens are reshaping how muscle-invasive bladder cancer is managed.
Pharma & Biotech

PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients

Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival

Read More